Draft guidance consultation
Closed for comments This consultation ended on at Request commenting lead permission
2 Information about voxelotor
Marketing authorisation indication
2.1 Voxelotor (Oxbryta, Global Blood Therapeutics) is indicated for 'treatment of haemolytic anaemia due to sickle cell disease in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics for voxelotor.
Price
2.3 The list price of voxelotor is confidential. The company has a commercial arrangement, which would have applied if voxelotor had been recommended.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation